Latest news

• Roche wins European approval for bleeding disorder treatment Hemlibra

  The European Commission (EC) has approved Roche’s highly anticipated haemophilia treatment Hemlibra (emicizumab). ... Both results showed a statistical significant reduction in treated bleeds for patients on Hemlibra compared to those not taking

• Roche faces biosimilar blitz in 2018

  Co’s Keytruda (pembrolizumab), and Hemlibra which has bagged US approval to treat patients with haemophilia A. ... US. Schwan added: “I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional

• Roche wins CHMP backing for Hemlibra

  Roche wins CHMP backing for Hemlibra. Haemophilia A treatment on course for European approval. ... If Hemlibra is passed it will be the first new medicine to treat haemophilia A with inhibitors in Europe in over 20 years.

• FDA lifts clinical hold on Sanofi’s haemophilia drug

  If approved, fitusiran will launch into a market already addressed in part by Roche’s Hemlibra (emicizumab-kxwh) which was approved by the FDA last month to prevent or reduce bleeding ... Hemlibra has been tipped to become a $1.5bn product by some

• New data could unlock bigger market for Roche’s Hemlibra

  New data could unlock bigger market for Roche’ s Hemlibra. Trial shows it ‘significantly’reduced bleeds in some haemophilia A patients. ... Hemlibra is the first product to show superior efficacy to factor VIII prophylaxis, ”commented Sandra